Literature DB >> 18003735

Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Milloni B Patel1, Noah G Hoffman, Ronald Swanstrom.   

Abstract

The V3 region of the human immunodeficiency virus type 1 gp120 Env protein is a key domain in Env due to its role in interacting with the coreceptors CCR5 and CXCR4. We examined potential subtype-specific V3 region differences by comparing patterns of amino acid variability and probing for subtype-specific structures using 11 anti-V3 monoclonal antibodies (V3 MAbs). Differences between the subtypes in patterns of variability were most evident in the stem and turn regions of V3 (positions 9 to 24), with the two subtypes being very similar in the base region. The characteristics of the binding of V3 MAbs to Env proteins of the subtype B virus JR-FL and the subtype C virus BR025 suggested three patterns, as each group of MAbs recognized a specific conformation- or sequence-based epitope. Viruses pseudotyped with Env from JR-FL and BR025 were resistant to neutralization by the V3 MAbs, although the replacement of the Env V3 region of the SF162 virus with the JR-FL V3 created a pseudotyped virus that was hypersensitive to neutralization. A single mutation in V3 (H13R) made this chimeric Env selectively resistant to one group of V3 MAbs, consistent with the mAb binding properties. We hypothesize that there are intrinsic differences in V3 conformation between subtype B and subtype C that are localized to the stem and turn regions and that these differences have two important biological consequences: first, subtype B and subtype C V3 regions can have subtype-specific epitopes that will inherently limit antibody cross-reactivity, and second, V3 conformational differences may potentiate the frequent evolution of R5- into X4-tropic variants of subtype B but limit subtype C virus from using the same mechanism to evolve X4-tropic variants as efficiently.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18003735      PMCID: PMC2224581          DOI: 10.1128/JVI.01444-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

1.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates.

Authors:  Mia Coetzer; Tonie Cilliers; Li-Hua Ping; Ronald Swanstrom; Lynn Morris
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

3.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Covariability of selected amino acid positions for HIV type 1 subtypes C and B.

Authors:  Peter B Gilbert; Vladimir Novitsky; Max Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2005-12       Impact factor: 2.205

5.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

6.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

7.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

8.  Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Susan Zolla-Pazner; Ian A Wilson
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; W J Honnen; S C Kayman; M K Gorny; S Zolla-Pazner; Abraham Pinter
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

10.  Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.

Authors:  M T Roos; J M Lange; R E de Goede; R A Coutinho; P T Schellekens; F Miedema; M Tersmette
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

View more
  34 in total

1.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

2.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

3.  V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.

Authors:  Reem Berro; Per Johan Klasse; Martin R Jakobsen; Paul R Gorry; John P Moore; Rogier W Sanders
Journal:  Virology       Date:  2012-03-16       Impact factor: 3.616

Review 4.  Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.

Authors:  Chaozai Zhang; Ruohan Zhu; Qizhi Cao; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-04

5.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

6.  Evolution of CCR5 use before and during coreceptor switching.

Authors:  Mia Coetzer; Rebecca Nedellec; Janelle Salkowitz; Sherry McLaughlin; Yi Liu; Laura Heath; James I Mullins; Donald E Mosier
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

7.  Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Authors:  Ralph Pantophlet; Terri Wrin; Lisa A Cavacini; James E Robinson; Dennis R Burton
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

8.  HIV-1 Populations in Semen Arise through Multiple Mechanisms.

Authors:  Jeffrey A Anderson; Li-Hua Ping; Oliver Dibben; Cassandra B Jabara; Leslie Arney; Laura Kincer; Yuyang Tang; Marcia Hobbs; Irving Hoffman; Peter Kazembe; Corbin D Jones; Persephone Borrow; Susan Fiscus; Myron S Cohen; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

9.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.

Authors:  Reem Berro; Rogier W Sanders; Min Lu; Per J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

10.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.